Free Trial
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:RANI

Rani Therapeutics Q3 2026 Earnings Date & Estimates

Rani Therapeutics logo
$0.80 +0.01 (+0.88%)
Closing price 04:00 PM Eastern
Extended Trading
$0.79 -0.01 (-1.25%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rani Therapeutics is expected to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Rani Therapeutics in Q3 2026

Rani Therapeutics is expected to post earnings of -$0.05 per share on revenue of $1.28 million. In the same quarter a year earlier Rani Therapeutics reported -$0.12 per share. Rani Therapeutics last reported on August 13, 2026, posting -$0.04 per share and beating the -$0.05 consensus estimate. Rani Therapeutics has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.05
Expected Revenue
$1.28 million
Prior-Year EPS
-$0.12

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.04 (Beat by +$0.01)
Last Quarter Revenue
$1.71 million
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Rani Therapeutics Q3 2026 Earnings FAQ

Rani Therapeutics (NASDAQ:RANI) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Rani Therapeutics' Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Rani Therapeutics to post earnings of -$0.05 per share for Q3 2026.

The consensus revenue estimate for Rani Therapeutics is $1.28 million for Q3 2026.

Rani Therapeutics Earnings Headlines

Rani Therapeutics Holdings, Inc. Announces Acceptance Of RaniPill Capsule Platform Technology Into U.S. Food And Drug Administration Emerging Technology Program
October 6 at 2:41 PM  |  marketscreener.comM
Rani Therapeutics' RaniPill Accepted Into FDA Emerging Technology Program
October 5, 2026  |  rttnews.comhttps://www.rttnews.com/3696565/rani-therapeutics-ranipill-accepted-into-fda-emerging-technology-program.aspx
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
October 9 at 1:00 AM  |  Chaikin Analytics (Ad)
Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)
October 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/05/3374470/0/en/rani-therapeutics-announces-acceptance-into-u-s-fda-s-emerging-technology-program-etp.html
Rani Therapeutics to Participate in Upcoming September Conferences
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3357608/0/en/rani-therapeutics-to-participate-in-upcoming-september-conferences.html
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI) and Sanofi (OtherSNYNF)
August 25, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SNYNF/pressreleases/4015435/analysts-offer-insights-on-healthcare-companies-rani-therapeutics-holdings-rani-and-sanofi-othersnynf/
See More Rani Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rani Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rani Therapeutics and other key companies, straight to your email.

About Rani Therapeutics

Rani Therapeutics (NASDAQ:RANI) is a biotechnology company developing oral delivery technologies for biologic medicines that are typically administered by injection. The company’s platform is designed to transport therapeutic molecules through the stomach and release them in the small intestine, where they can be absorbed into the bloodstream.

Its primary technology, the RaniPill capsule, is a robotic oral delivery system intended to deliver biologics, peptides and other large-molecule therapies. The company is developing proprietary product candidates based on this platform, including programs aimed at conditions such as osteoporosis and other chronic diseases. Its pipeline has included RT-102, an oral formulation of parathyroid hormone-related therapy, as well as additional candidates involving peptide and antibody-based medicines.

Rani Therapeutics was founded by entrepreneur and medical-device innovator Mir Imran and is headquartered in San Jose, California. The company’s activities have focused on research, development and clinical testing rather than broad commercial distribution, with its programs being evaluated through clinical and regulatory processes. Talat Imran has served as the company’s chief executive officer, while Mir Imran has remained associated with the company as its founder and chairman.

View Rani Therapeutics Profile
Earnings Tools